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Our recent studies have shown a link between Adenovirus-5 (Ad-5) and elevated 
lipids, which prompted the hypothesis that Ad-5 infection might augment hepatic and/or 
adipose tissue lipid metabolism. To test our hypothesis, mice were infected with Ad-5 and 
screened for changes in lipogenesis and plasma markers associated with the metabolic 
syndrome.  We observed increased expression of sterol regulatory element binding protein 
1 (SREBP-1) in infected liver tissues, but not in adipose tissues and this correlated with 
elevated plasma and hepatic triglyceride levels.  Elevated expression of adiponectin was 
seen in Ad-5 infected adipose tissues and this correlated with phosphorylated AMPK in 
infected liver tissues.  These data suggested that the AMPK pathway was activated in 
livers of Ad-5 infected mice. Indeed, we observed reduced expression of PEPCK, a 
downstream target of AMPK in livers of Ad-5 infected mice.  As PEPCK is an enzyme 
essential for gluconeogenesis, we hypothesized that Ad-5 infection would reduce blood 
sugar. Indeed, infected mice exhibited a transient decline in plasma glucose.   
The increase in SREBP1 levels in Ad-5 infected hepatic tissues was evaluated by 
looking at Ad-5 infected HepG2 cells.  Ad-5 is thought to mimic insulin’s actions in which 
the PI3K pathway is activated.  We hypothesized that Ad5-induced SREBP-1 expression 
levels are mediated through the induction of PKC !/"/!, and not through Akt because it has 
been shown that PKC !/"/! mediates insulin-dependent lipogenesis.  To test our hypothesis, 
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HepG2 cells were infected with Ad-5 and screened for downstream targets of the PI3K 
pathway.  Through western blot analyses, we observed increased levels of phosphorylated 
PKC !/"/!.  These results prompted the use of PKC pan inhibitor to see whether Ad-5 
induced SREBP-1 levels would be down regulated.  Indeed, with the presence of the PKC 
pan inhibitor, SREBP-1 expression levels were reduced.   
Together, these studies suggest that Ad-5 induces changes in gene expression, 
glucose, and lipid metabolism; which prompts the hypothesis that this common respiratory 
pathogen may be associated with the Metabolic Syndrome, and this may preclude its use as 
a vector for gene therapy. 
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CHAPTER 1:  INTRODUCTION 
 
A group of metabolic risk factors referred to as Metabolic Syndrome (MS) were 
officially defined by the World Health Organization in 1998.  MS is comprised of five 
risk factors which include obesity, high serum triglyceride levels, low serum high - 
density lipoprotein (HDL) cholesterol levels, hypertension, and increased fasting blood 
glucose levels.  It has been noted that MS is a huge risk factor for diabetes, stroke, 
cardiovascular disease, infertility, cancer, liver disease, and cerebrovascular disease 
(Cornier et al., 2008).  The underlying factor that contributes to MS is aberrant lipid 
metabolism that further plays a role in contributing to these metabolic diseases.  The 
major focus of this study is to investigate alterations in lipid metabolism by looking at 
cellular signaling components in the liver, as well as in adipose tissue. 
Studies have shown that genetic, behavioral, and environmental factors may all 
account as causative factors of dyslipidemia (So et al., 2005).   Recent studies have 
associated viral, parasitic, and bacterial infections to changes in lipid metabolism, 
obesity, and fatty liver disease.  Most importantly, viral infections have been overlooked 
as potential contributory factors affecting metabolic syndrome (So et al, 2005).  It has 
been studied that enteroviruses, such as the coxsackie B4 virus, can infect human islet 
cells and trigger the destruction of # cells (Berg et al., 2007).  This can lead to Type I 
diabetes, as well as to decreased levels of insulin secretion (Dotta F. et al., 2007).  One of 
the most studied viruses associated with chronic liver disease, which exemplifies 
symptoms such as insulin resistance and visceral fat obesity is the Hepatitis C virus 
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(HCV) (Saito et al., 2007).  It is known that HCV infection leads to lipid accumulation in 
hepatocytes due to increased expression of lipogenic genes, which includes Sterol 
Regulatory Element Binding Protein 1 (SREBP-1) (Siddiqui et al., 2007).   
 
1.1 STEROL REGULATORY ELEMENT BINDING PROTEINS 
 
 Streol Regulatory Element Binding Proteins (SREBPs) are members of the basic-
helix-loop-helix-leucine zipper (bHLH-Zip) family of transcription factors that encode 
genes involved in triglyceride, cholesterol, as well as fatty acid synthesis (Figure 1) 
(Horton et al., 2002).  Fatty acid synthesis associated genes such as fatty acid synthase 
(FAS) and acety CoA caboxylase (ACC), as well as cholesterol associated genes such as 
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase) and squalene 
synthase are some of the genes regulated by mature SREBP (Eberle et al., 2004).  There 
are three SREBP isoforms:  SREBP-1a, SREBP-1c, and SREBP2.  SREBP-1 has two 
alternative transcriptional start sites, which result in production of SREBP-1a and 
SREBP-1c.  SREBP-1a can activate all SREBP-responsive genes, including genes for 
cholesterol, fatty acid, and triglyceride synthesis.  SREBP-1c, on the other hand, is more 
specific and can only enhance transcription of genes responsible for fatty acid and 
triglyceride synthesis.  SREBP2 is restricted to cholesterol synthesis and is the 
predominant form in the liver, along with SREBP-1c  (Horton et al., 2002). 
  
 SREBPs are activated through a series of proteolytic processing steps.  Once they 
are synthesized as inactive precursors of about 1150 amino acids, they are bound to the 
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endoplasmic reticulum (ER).  The inactive precursor form of SREBP has three domains:  
an NH2-terminal domain that binds DNA, two hydrophobic transmembrane-spanning 
segments, and a COOH-terminal domain, which performs the essential regulatory 
function (Figure 2)  (Goldstein and Brown, 1997).  Processing of SREBP occurs with the 
help of three proteins, namely an escort protein called SREBP cleavage-activating protein 
(SCAP), and two proteases Site-1 protease (S1P) and Site-2 protease (S2P).  Once the 
newly synthesized precursor SREBP is bound to the ER, its COOH-terminal regulatory 
domain binds to COOH-terminal domain of SCAP.  SCAP is known to interact with 
insulin induced gene proteins (Insig), which help retain SCAP/SREBP complex in the ER 
(Eberle et al., 2004).  SCAP not only acts as an escort of SREBP from the ER, but it is 
also a sensor of sterols in the cells.  Therefore, once the cells are depleted of sterols, 
SCAP’s association with Insig decreases, and this allows SCAP to bring about 
translocation of SREBP from the ER to the golgi apparatus, in which S1P and S2P reside.  
S1P cleaves SREBP at the luminal loop between its two membrane-spanning segments, 
and consequently a second cleavage by S2P occurs in which the NH2-terminal domain 
(nuclear SREBP – nSREBP) is released.  The “activated” nSREBP is then translocated to 
the nucleus, where it is able to bind to genes containing sterol response elements (SREs), 
thus promoting gene expression.  If cells are in excess of sterols, then SCAP senses this 
in the cells and changes its conformation so that SCAP/SREBP complex is not 
translocated from the ER to the golgi apparatus because SCAP is unable to dissociate 
from Insig (Eberle et al., 2004).  SREBP, therefore, cannot be cleaved by proteases 
residing in golgi apparatus, and thus transcription of target genes does not occur  
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(Goldstein and Brown, 1999).  Thus, the levels of sterols in the cells control the mature 
nuclear pool of SREBP in terms of expression at the precursor level, which then gets 
processed to its mature form.  Overall, SREBP is essential in lipid metabolism and fatty 
acid synthesis in the liver.   
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SUMMARY OF SREBP-1C AND SREBP-2 
 
 
Figure 1. Summary of SREBP-1 and SREBP-2 downstream targets (Horton et al., 2002). 
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SREBP-1A AND SREBP2 DOMAIN STRUCTURES 
 
 
 
Figure 2.  SREBP-1a and SREBP2 domain structures (Goldstein and Brown, 1997). 
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1.2 CHARACTERIZATION OF ADENOVIRUS -5 
 
 As mentioned previously, several viruses elicit different responses such as 
targeting pancreatic islet cells leading to type I diabetes, or targeting the liver and leading 
to lipid accumulation and visceral fat obesity.  Recently, immense amount of studies have 
focused on viral infections as a potential cause for changes in lipid metabolism that can 
lead to metabolic syndrome.  It is of great interest to study adenovirus infection as a link 
to changes in lipid metabolism, as viral vectors are often used in gene therapy.     
  Adenovirus was first isolated and cultured from tonsils and adenoid tissue in 
1953 (Shayakhmetov and Di Paolo, 2009).  Currently, there are 52 identified human 
adenovirus serotypes, divided into six species (A-F).  Adenovirus is commonly known to 
cause infections of the upper respiratory tract, as well as the gastrointestinal tract 
(Goncalves and Vries, 2006).  There are many widely used applications for adenovirus 
vectors, but mainly they have been used for gene transfer studies.  One of the main 
adenoviruses studied to date is Adenovirus-5 (Ad-5), which has been mostly used as a 
vector for gene delivery.  It belongs to subgroup C of the adenoviruses, and commonly 
causes upper respiratory tract infections.  It is a non-enveloped virus with double-
stranded DNA of about 36 kilobases in size (Greber and Meier, 2004).  Ad-5 has been 
proposed for use in human gene therapy, mainly because it can be easily produced in 
large quantities and large gene constructs can be inserted into the deleted regions of the 
virus (Young et al., 2006).   
 Ad-5 genes are divided into early (E) and late (L) regions.  There are five early 
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genes, each of which is comprised of a transcriptional unit with sites for transcriptional 
initiation, termination, and splicing.  The early genes are responsible for initiation of viral 
replication, as well as for expression of non-structural, regulatory proteins (Curiel et al., 
2006; Templeton, 2008).  The late genes are transcribed post beginning of DNA 
replication stage and are responsible for encoding the structural proteins for the virus.  
The E1A coding region of the adenovirus is required for transcription of early genes such 
as E1B, E2, and E4.  This helps ensure that proteins required for viral replication are 
properly expressed.  E2 and E4 regions promote expression of proteins necessary for late 
gene transcription, while the E3 region of the adenovirus codes for proteins that help the 
virus evade host defenses.  The E1B region products are also able to transiently bind to 
apoptotic genes and inhibit the apoptotic pathway of the host cell ensuring that viral 
replication occurs (Templeton, 2008).       
 As mentioned earlier, Ad-5 of the group C adenoviruses, is the mostly commonly 
used adenovirus for transgene expression because large constructs can be inserted into its 
genome  (Young et al., 2006).  Ad-5 is rendered a replication deficient virus due to a 
deletion in the E1 coding region, as well as a partial or a complete deletion of the E3 
region  (McCaffrey et al., 2008).  It is in the E1 and E3 deleted regions where the gene of 
choice is inserted.  Numerous clinical trials have been conducted with the use of Ad-5 for 
transgene expression, but several issues with implementing this system have also 
occurred.  In one of the earliest studies using Ad-5 mediated vector system complications 
occurred in which there was only a transient expression of the transgene, and almost all 
of the patients elicited an immune response, but had no benefit from the trial overall 
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(Young et al., 2006).  An explanation for this occurrence might be the fact that early in 
life, humans develop antibodies to group C adenoviruses, which include Ad-5, and thus 
the virus may potentially be neutralized (Young et al., 2006).  Also, majority of the 
adenoviruses end up in the liver, and may not reach their target tissues; that is one of the 
biggest challenges presented with using Ad-5 as a vector is tissue specificity and delivery 
of the transgene (Bergelson and Zhang, 2005).   
 The structure of Ad-5 is quite complex and its attachment and internalization into 
non-target host cells presents a problem with using Ad-5 as a gene delivery system.  Ad-5 
has an icosahedral capsid, which contains viral DNA and core proteins, and is mainly 
composed of hexon protein.  Each vertex of the icosahedron is capped by a penton base, 
from which an elongated trimeric penton fiber projects.  The fiber has two ends, a 
proximal and a distal end.  The proximal end is the end attached to the penton base, but it 
is the distal end that forms a globular “knob” which serves as an attachment site of 
adenoviruses to the host cell.  The globular “knob” attaches to the Coxsackie and 
adenovirus receptor (CAR) with high affinity, which is followed by penton proteins, 
containing Arginine-Glycine-Aspartate (RGD) motif that interact with integrin co-
receptors $v #3 and $v #5, and thus trigger intergrin-mediated endocytosis  (Bergelson 
and Zhang, 2005).  Once this process occurs, the virus enters the cell in a clathrin-coated 
vesicle, from which it escapes and goes to the cytoplasm and eventually enters the 
nucleus.  This internalization of the adenovirus into the host cells has been shown to lead 
to activation of the PI3K pathway and subsequent activation of its downstream factors, 
such as Akt and PKC (Nemerow et al., 1998).  Studies have also shown that virus 
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internalization and nuclear localization is rapid, occurring as fast as one-hour post 
infection (Wickham et al., 1993; Templeton, 2008). 
 It is suggested that adenovirus vectors elicit an early inflammatory response that 
is transcriptionally independent, meaning it is not due to viral gene transcription 
(Muruve, 2004).  In clinical studies, it has been proven difficult to target the adenovirus 
vector to specific tissue types, mainly due to the fact that most adenovirus serotypes bind 
to the widely distributed CAR receptor.   CAR serves as an attachment site for the 
adenovirus, while $v integrins are used for viral internalization into the cell.  Also, since 
CAR is so widely distributed, it presents a challenging task for adenovirus-mediated gene 
therapy as the virus can target non-target tissues, and cause broad tissue tropism (Greber 
and Meier, 2004).  However, in vivo mouse studies have revealed that adenovirus protein 
levels are two fold higher in the liver, compared to other organs such as the spleen, lungs, 
kidneys, stomach, and the heart.  It was also concluded that the liver is the major organ to 
sequester adenovirus particles from the blood (Jiang et al., 2010).  Since the liver is the 
major target for adenovirus infection, it is of great interest to study the effects adenovirus 
might potentially have on the liver and its surrounding organs.   
 Since Ad-5 has been widely used for gene therapy and it is known to target the 
liver, there have been several studies characterizing the effects of viral infections on liver 
and adipose tissues.  Hepatitis C Virus (HCV) has been associated with liver cirrhosis, as 
well as hepatosteatosis (Saito et al., 2007).  More importantly, it has been characterized to 
cause increased lipogenesis through the increase in expression of SREBP-1 and SREBP2 
transcription factors (Siddiqui et al., 2009; Koike et al., 2010).  Not only does HCV 
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infection cause altered lipid metabolism, but there is evidence which links adenovirus 
infection to aberrant lipid metabolism as well.  One of the most prominent studies by Dr. 
Nikhil Dhurandhar focuses on the characterization of Adenovirus-36 (Ad-36) and its 
effects on adipose tissue functions.  His studies lead to a belief that there is a correlation 
between Ad-36 infection and aberrant lipid metabolism, as he has shown that wild-type 
Ad-36 induces adiposity, leading to an accumulation of triglycerides in adipose tissue 
(Dhurandhar et al., 2004; Dhurandhar et al., 1999).  As mentioned previously, FAS and 
ACC are downstream targets of SREBP-1, which are involved in the fatty acid synthesis 
pathway.  It was shown that ACC and FAS levels are significantly increased in Ad-36 
infected rat adipose tissues (Vangipuram et al., 2007).  Atkinson’s group focused on 
studying adenovirus effects on adipose tissues as well, in which they demonstrate that 
Ad-37, but not Ad-2 increase adiposity in mice (Atkinson et al., 2005).  Ad-36 and Ad-37 
are of group D adenoviruses, while Ad-2 is of the group C human adenoviruses, which 
may potentially explain the difference in their findings.  Another interesting finding by 
So et al, has revealed that Ad-5 increases adiposity (So et al., 2005).  So far evidence 
points out that of group C adenoviruses, Ad-5, but not Ad-2, increase adiposity.  First 
generation replication deficient Ad-5 is commonly employed as an expression vector for 
gene transfer, and is often used in gene therapy clinical trials (Muruve, 2004, Young et 
al., 2006).  This may potentially become a problem in clinical trials, if replication 
deficient Ad-5 is linked to changes in lipid metabolism.  Therefore, further studies need 
to be conducted to test whether Ad-5 may be a potential explanation for aberrant lipid 
metabolism in obese and diabetic individuals. 
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1.3 ADENOVIRUS-5 AND GLUCONEOGENESIS 
 
 As just mentioned, Ad- 5 has been shown to be associated with increased 
adiposity, which prompts the hypothesis that it promotes aberrant or excessive 
adipogenesis.  These events may lead to increased insulin secretion, or impaired lipid and 
glucose metabolism.  It has been shown that Ad-36 acts as an adipogenic agent, 
increasing adiposity in infected chickens, mice, and rat animal models (Dhurandhar et al., 
2000c).  Proadipogenic genes such as fatty acid synthase and adiponectin are upregulated 
with Ad-36 infection in mice (Dhurandhar et al., 2008).  As mentioned previously, fatty 
acid synthase is a target gene for SREBP-1, which is important in the fatty acid synthesis 
pathway.  Adiponectin, on the other hand, is an “adipokine” produced by the adipose 
tissue that is essential in anti-diabetic and anti-inflammatory effects (Korbut et al., 2006).  
  Adipose tissue is thought of as not only a major organ for energy storage, but 
also as an important endocrine organ, which produces a number of hormones and 
cytokines that regulate insulin sensitivity (Haluzik et al., 2004).  Some of these include 
leptin, adiponectin, resistin, which fall under the “adipokines” category, as well as some 
classical cytokines such as TNF-alpha, IL-6, and IL-1 that are most likely released by 
inflammatory cells which have infiltrated the adipose tissue (Korbut et al., 2006).  Of all 
the bioactive mediators released from adipose tissue, leptin and adiponectin are most 
abundantly expressed within the adipose tissue, and have been the most studied.   
 Adiponectin, also known as adipocyte complement-related protein (Acrp30) is a 
30kD in size protein, which can oligomerize into one of three major forms:  a low 
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molecular weight (LMW) trimer, a medium molecular weight (MMW) 180kD hexamer, 
or a high molecular weight (HMW) 400-600kD multimer (Korbut et al., 2006; You et al., 
2008).  Interestingly, trimers have been shown to have the highest biological activity in 
adipose tissues (Korbut et al., 2006).  Adiponectin consists of four domains including a 
signal peptide at the N terminus, a short variable region, a collagenous domain, and a C-
terminal globular domain (Haluzik et al., 2008; You et al., 2008).  In the blood, 
adiponectin levels are relatively high ranging from 5-10 ug/ml, which comprises about 
0.01% of total plasma proteins (Korbut et al, 2006; You et al., 2008).  There are two 
forms of adiponectin, a full-length adiponectin and a C-terminal globular adiponectin 
domain (gAd) that was generated from the full-length protein through a series of 
proteolytic processing steps.  As there are two forms of adiponectin, there are also two 
major adiponectin receptors (You et al., 2008).  They are structurally related integral 
plasma membrane proteins with seven membrane-spanning domains.  The two receptors 
are termed adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2) (You 
et al., 2008; Korbut et al., 2006).  AdipoR1 has a high affinity for the globular form of 
adiponectin and a low affinity for full-length adiponectin, whereas AdipoR2 is 
intermediate in its preference.  Of the two receptors, AdipoR2 is primarily expressed in 
the liver, but AdipoR1 is mostly expressed in skeletal muscle (Korbut et al., 2006).   
 Until recently, not much was known about adiponectin and its signaling effects in 
adipose tissue as well as other target tissues.  It is known that adiponectin is released by 
adipocytes and has major anti-diabetic properties, in which it regulates energy 
homeostatis and lipid metabolism (Musi et al., 2006).  Obesity and type 2 diabetes have 
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been associated with decreased levels of adiponectin and it is known that adiponectin 
decreases insulin resistance, and suppresses hepatic glucose production (Mazzone and 
Fantuzzi, 2007).  Adiponectin also acts as a major ‘adipokine’ and is related to several 
metabolic processes in the liver.   
 Adiponectin signaling has been associated with the activation of AMP-activated 
protein kinase (AMPK).  Once adiponectin is released from adipose tissue, it interacts 
with adiponectin receptors (AdipoRs) in the liver and implements its effects on lipid 
metabolism by stimulating several signaling cascades including hepatic AMPK, PPAR-
gamma coactivator alpha (PGC-1alpha), and SREBP-1 (Musi et al., 2006; Viollet et al., 
2006).  It has been suggested that in the liver AMPK is activated with full-length 
adiponectin.  When adiponectin stimulates AMPK signaling, several downstream 
signaling events occur which bring out a reduction in lipid synthesis, and an indirect 
enhanced fatty acid oxidation (Kadowaki et al., 2002).  So once AMPK is activated, it 
phosphorylates one of its downstream targets acetyl CoA carboxylase (ACC).  Upon this 
phosphorylation, ACC becomes inactive and this results in a decrease in production of 
malonyl-CoA, which acts as an inhibitor of the carnitine palmitoyltransferase I (CPT-1).  
Once the inhibition of CPT-1 is relieved, it is able to transport fatty acids into the 
mitochondria for %-oxidation (Kadowaki et al., 2002; You et al., 2008; Violet et al., 
2007).  These events lead to lipid breakdown, and a decrease in lipid content in the liver.  
Not only does this signaling cascade increase lipid breakdown, but it also improves 
insulin sensitivity (Kadowaki et al., 2007).   
 AMPK activation also has affects on SREBP-1 expression in the liver.  When 
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adiponectin activates AMPK in the liver, it leads to decreased expression of SREBP-1c 
mRNA and protein levels, which results in downregulation of genes regulated by 
SREBP-1c (Viollet et al., 2006).  These genes primarily include ACC and FAS, which 
are lipogenic enzymes in the liver.  Overall, this contributes to a reduction in hepatic lipid 
synthesis and has implications in insulin resistance, and dyslipidimia.   
 Adiponectin roles are not limited to reduction in hepatic lipid content, but also 
extend their role in gluconeogenesis through the activation of AMPK signaling cascade.  
It has been shown that upon activation of AMPK, there is a reduction in expression levels 
of molecules such as phosphoenolpyruvate caboxykinase (PEPCK) and glucose-6-
phosphatase (G6Pase) in hepatocytes (Chung et al., 2010).  These molecules are the rate-
limiting enzymes involved in hepatic gluconeogenesis, and their decrease marks an 
overall decrease in hepatic glucose production (Viollet et al., 2006).  Studies have shown 
that activation of AMPK mimics insulin’s effects on hepatic gluconeogenesis, in which a 
reduction in gluconeogenic genes is observed (Lochhead et al., 2000).  
 Reduction of gluconeogenesis via activation of AMPK is currently under study, 
but some research has shown that an important downstream factor of AMPK has emerged 
as a critical regulator of gluconeogenesis.  Transducer of regulated CREB activity 2 
(TORC2) has been shown to be the critical regulator of gluconeogenesis in mice (Viollet 
et al., 2006).  It acts as an activator during fasting conditions, where it leads to 
recruitment of peroxisome proliferator-activated receptor-coactivator (PGC-1alpha), thus 
driving transcription of PEPCK and G6Pase in association with hepatocyte nuclear factor 
4 (HNF4alpha) and the forkhead family activator FoxO1.  AMPK was found to 
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phosphorylate TORC2, which promotes its binding to the 14-3-3 proteins.  These events 
block TORC2 translocation to the nucleus, so it is sequestered in the cytoplasm and is 
unavailable for the activation of its downstream targets such as PEPCK and G6Pase 
(Viollet et al., 2006; Weickert and Pfeiffer, 2006).  Interestingly, it is worth mentioning 
that there is evidence for repression of G6Pase during glucose starvation or treatment 
with aminoimidazole carboxamide ribonucleotide (AICAR) due to repression of cellular 
levels of FoxO1 protein (Barthel et al., 2002).  FoxO1 is part of a family of forkhead 
transcription factors that behave similarly to TORC2, in which when phosphorylated they 
are sequestered from the nucleus through interaction with 14-3-3 proteins (Unterman et 
al., 2006).  Further evidence suggests that once FoxO1 is sequestered in the cytosol, they 
are subjected to polyubiquitination and degradation (Carlsson and Mahlapuu, 2002).  
There is not a lot of evidence to confirm that AMPK directly phosphorylates FoxO1, thus 
driving the reduction of genes associated with gluconeogenesis, but of the research 
currently published, these events are suggestive (Fisslthaler et al., 2007).   
 Although FoxO1 is suggested to be directly phosphorylated through AMPK 
activation, it is also activated through the phosphoinositide 3-kinase/Akt (PI3K/Akt) 
pathway (Carlsson and Mahlapuu, 2002).  Hepatic PI3K/Akt phosphorylates FoxO1, 
which contains 3 Akt phosphorylation sites.  This results in FoxO1 exclusion from the 
nucleus with the help of 14-3-3 binding to the phosphorylated Akt site on FoxO1 and 
leading to masking of the nuclear localization sequence (Weickert and Pfeiffer, 2006).  
Overall, these events lead to a decrease in PEPCK and G6Pase gene expression.    
 The PI3K/Akt pathway is not only important in gluconeogenesis in which it can 
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dampen expression of gluconeogenic genes, but it is also a crucial pathway in lipid 
metabolism.  Immense amount of research has been conducted to link insulin regulation 
of hepatic lipid metabolism through the induction of SREBP-1c.  Insulin induces hepatic 
SREBP-1c expression through the PI3K/Akt pathway, leading to increased synthesis of 
fatty acids and triglycerides (Taniguchi et al., 2006).  Effectors of the PI3K pathway 
include Akt and the atypical protein kinase C (PKC !/"/!), which are both essential for 
insulin-stimulated lipid synthesis (Taniguchi et al., 2007).  The mechanism of how PI3K 
pathway generates the upregulation of SREBP-1c is not well understood, but it has been 
shown that Akt is responsible for mediation of insulin-dependent hepatic glucose 
metabolism, while PKC !/"/! has been linked to the insulin-dependent induction of 
expression of SREBP-1c (Taniguchi et al., 2006).   
 The liver is an organ that plays a crucial role in regulation of glucose and lipid 
metabolism.  On the molecular level, these mechanisms all work together to create a 
balance between lipid breakdown and accumulation.  Along with the liver, adipose tissue 
has emerged as an important endocrine organ that plays a role in not only energy storage, 
but also in production of hormones that can act as ‘adipokines’ to regulate cellular 
processes in the liver.  Ad-5 has been linked to aberrant lipid metabolism, as well as to 
tropism to the liver.  It is based on the aforementioned studies and research that we 
attempted to characterize the effects of Ad-5 infection on metabolism in hepatic and/or 
adipose tissues. 
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HYPOTHESIS 
 
 Based on the aforementioned studies and previous studies conducted in our lab, we 
hypothesize that Ad-5 infection induces changes in gene expression, glucose, and lipid 
metabolism.  Here we investigate the role of Ad-5 in liver and adipose tissues, and try to 
characterize the mechanism of Ad-5 in aberrant lipid metabolism. It is suggestive that this 
common respiratory pathogen may be associated with the Metabolic Syndrome, and this 
may preclude its use as a vector for gene therapy. 
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CHAPTER 2:  METHODS AND MATERIALS 
 
Cell Culture - Human hepatoma cells (HepG2 cells) obtained from ATCC were 
maintained in Minimum Essential Medium (MEM) supplemented with 10% heat 
inactivated fetal calf serum, 2mM glutamine, 1% penicillin/streptomycin, 1mM 
nonessential amino acids, and 0.1mM sodium pyruvate. All cells were maintained at 37°C 
at 7.5% CO2 humidity.   
 
Infection of HepG2 cells - HepG2 cells were plated at 5 x 10
6 
cells/well in 6 well plates.  
Following adherence to the plates, HepG2 cells were infected with Ad-5 virus at 
multiplicity of infection (MOI) of 15 and harvested up to 72 hours post infection.  For cells 
not harvested at 16 hours post infection, the virus was removed and cells were replenished 
with fresh media 16 hours post infection for harvesting at later time points. 
 
PKC zeta inhibition - HepG2 cells were plated at 5 x 10
6 
cells/well in 6 well plates.  
Following adherence to plates, cells were pre-treated with myristoylated PKC zeta peptide 
inhibitor at 25uM per well for 1 to 2 hours.  Following pre-treatment, cells were then 
infected with Ad-5 at MOI of 15.  Virus and PKC zeta inhibitor containing media was 
removed 16 hours post infection and cells were replenished with fresh media or with fresh 
PKC zeta inhibitor.  Cells were then harvested at 72 hours post infection. 
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PKC inhibition using siRNA –  siRNA oligos against PKCi were obtained from Ambion.  
The sense sequence was 5’-GAGACCUAAUGUUUCAUAUtt-3’, while the antisense was 
5’-AUAUGAAACAUUAGGUCUCct-3’. Silencer Validated siRNA, Silencer negative 
siRNA control were purchased from Ambion.  HepG2 cells were plated at 5 x 10
6 
cells/well in 6 well plates and transfected with validated siRNA and negative siRNA 
control at final concentration of 100nM using siPORTNeoFX Transfection Agent 
according to manufacturer’s instructions (Ambion).  Plates were incubated at 37°C until 
harvest.  Cells were harvested at 24 and 48 hours post transfection, using RIPA buffer.  
Cells harvested at 72 hours post transfection were re-transfected at 48 hours following the 
same protocol, and harvested at 72 hours post transfection.   
 
Adenovirus Infection - C57BL/6 mice were infected by tail-veil injection with 1 x 10
11 
particles (~3.2 x 10
8
 PFU) of first generation replication-deficient adenovirus-5 which 
lacks E1A, E1B and E3 regions.  Mice were then sacrificed at indicated times post-
infection.  Adipose and liver tissues were extracted and flash frozen.   
 
Adipose and Liver Tissue Homogenate - Mouse adipose and liver tissue homogenates 
were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Piece 
Biotechnology).  Livers and adipose tissue were flash frozen post extraction.  Liver and 
adipose tissue homogenates were prepared using ~15mg of tissue.  Mouse livers were 
disrupted using a dounce homogenizer in a buffer containing 10mM HEPES (pH 7.4), 
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10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 50mM NaF, 1mM activated Na3VO4, 30mM 
Na4P2O7, 20mM 2-glycerophosphate, and 1% SDS with phosphatase inhibitor cocktail I 
(Sigma) and a complete protease inhibitor cocktail (Roche). 
 
HepG2 Cell Homogenates - HepG2 cells were incubated with calpain inhibitor I 
(25ug/ml) for two hours prior to harvest.  Cell homogenates were prepared in a buffer 
containing 20mM Tris-HCl (pH 7.5), 50mM NaCl, 50mM NaF, 30mM Na4P2O7, 20mM 2-
glycerophosphate, 1mM activated Na3VO4, 5mM EDTA, 2mM EGTA, pefabloc 
100mg/ml, PMSF 0.1M, and a complete protease inhibitor cocktail (Roche).   
 
Protein Analysis by Immunoblot - Proteins were separated by 10% SDS-PAGE and 
immunoblotted with antibodies such as pan p- PKC !/", total PCK !/", SREBP1, p-AMPK, 
total AMPK, ERK1/2, GAPDH, HDAC1, or actin.  Signals were detected with HRP-
coupled secondary antibodies (Pierce) and developed with chemiluminescent detection 
system from Amersham.  Signals were quantified using densitometric analysis (Alpha 
Inotech FC8800).   
 
qPCR Analysis – Mouse liver RNA was extracted using SV Total RNA Isolation System 
(Promega).  mRNA encoding PEPCK, G6Pase, SREBP1, SREBP2 and ACC were 
quantified by SYBR Green qPCR using the Brilliant QRT-PCR Core Reagent Kit, 1-Step 
(Stratagene).  Target gene expression was normalized to 18S RNA (control), quantified 
with TaqMan, One Step RT-PCR Master Mix Reagents were also used (Applied 
Biosystems).   
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Primers used were as follows: 
PEPCK Reverse:  5’-CTTCACTGAGGTGCCAGGAG-3’ 
PEPCK Forward: 5’-CTAACTTGGCCATGATGAACC-3’ 
SREBP1 sense:  5’-CACTGAAGCAAAGCTGAATAAATCTG-3’ 
SREBP1 antisense:  5’-AGTGATTTGCTTTTGTGTGCACTT-3’ 
SREBP2 sense:  5’- CAAGAGAAAGTTCCTATCAAGCAAGTG-3’ 
SREBP2 antisense:  5’- GTCCTTCAACTCTATGATTTTGTCGTT-3’ 
ACC sense:   5’- AGGATTTGCTGTTTCTCAGAGCTT-3’ 
ACC antisense:   5’- CAGGATCTACCCAGGCCACAT-3’ 
G6Pase Reverse:  5’- ACAGGTGACAGGGAACTGCT-3’ 
G6Pase Forward: 5’- TCGGAGACTGGTTCAACCTC-3’ 
18S sense:  5’-AAAATTAGAGTGTTCAAAGCAGGC-3’ 
18S antisense:  5’-CCTCAGTTCCGAAAACCAACAA-3’ 
18S probe:  5' - /56-FAM/CGAGCCGCCTGGATACCGCAGC/36-TAMSp/ - 3' 
 
Plasma analyses - Plasma lipids and glucose were measured by the Diagnostic 
Laboratories of the McGuire VA Hospital, Richmond, VA.  Thank you so much to Dr.W. 
Michael Pandak, who generously arranged for these analyses. 
 
Statistical Analysis - Data were analyzed with two-sided Student’s t-test with p < 0.05 
taken as the limit for statistical significance.  Some in vitro experiments were replicated at 
least three times. 
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CHAPTER 3:  RESULTS 
 
There have been numerous studies conducted implicating a correlation between 
viral infection and aberrant lipid metabolism.  Specifically, studies have shown that upon 
infection with wild-type Adenovirus-36 (Ad-36), mice exhibit an increase in body mass 
index due to accumulation of triglycerides (Dhurandhar et al., 2004).  More importantly, 
Ad-36 infected rat adipose tissues have elevated FAS and ACC levels, which are important 
downstream targets of SREBP-1, and are essential in the fatty acid synthesis pathway 
(Vangipuram et al., 2007).   Also, Adenovirus-5 (Ad-5) has been shown to increase 
adiposity, which has led us to hypothesize that replication deficient Ad-5 plays a role in 
lipid metabolism (So et al., 2005).  Therefore we wanted to investigate the role of Ad-5 in 
liver and adipose tissues, and characterize the mechanism by which it brings about aberrant 
lipid metabolism.  We hypothesized that Ad-5 infection would increase hepatic lipid 
synthesis and genes associated with lipid metabolism. 
3.1 AD-5 INDUCES SREBP-1 
 One of the first indications we received about the role of Ad-5 and its link to lipid 
metabolism was upon infection of C57BL/6 mice with replication deficient Ad-5.  Mice 
were sacrificed 4- and 5-days post infection, and livers and plasma were screened for genes 
associated with lipid metabolism.  Triglyceride levels in the plasma, as well as in the liver 
were significantly elevated in day-4 infected mice compared to uninfected mice (Figure 3A 
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and 3B).  On day-5 post infection, there was a significant increase in liver triglyceride 
levels, but not in the plasma (Figure 3A and 3B).  Cholesterol levels were also analyzed, 
and showed no change on days 4 and 5 when compared to uninfected mice in both plasma 
and liver tissue (Figure 3A and 3B).  An increase in triglycerides, but not cholesterol levels 
is an indication that there may be changes in genes associated with lipid metabolism.  One 
of these genes is Sterol Regulatory Element Binding Protein-1 (SREBP-1), which is 
involved in synthesis of fatty acids and triglycerides.  We wanted to see whether SREBP-1 
levels are increased in Ad-5 infected livers, which would be an indication that the increase 
in triglyceride levels upon Ad-5 infection is mediated through SREBP-1c.  We screened 
for SREBP-1 protein in liver homogenates, and observed an increase in SREBP-1 
precursor (125kd) levels in infected livers compared to uninfected livers, suggesting that 
Ad-5 induces SREBP-1 expression levels, thus driving an increase in triglyceride synthesis 
in infected mice (Figure 4).  To confirm our results that SREBP-1 protein is significantly 
increased in Ad-5 infected mice, we performed real time PCR (qPCR) to measure SREBP-
1 transcripts in livers of infected and uninfected mice.  SREBP-1 transcripts are 
significantly elevated in day-4 livers of infected mice, but this effect is transient as the 
levels begin to decline on day-5 post infection (Figure 5A).  To reiterate the importance of 
SREBP-1, we also measured acetyl CoA-carboxylase (ACC) transcipt levels, as ACC is a 
downstream target of SREBP-1 and is involved in synthesis of fatty acids and 
triglycerides.  We observed a significant increase in ACC transcript levels on day-4 and -5 
post infection, suggesting that Ad-5 infection leads to an increase in trancriptionally active 
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mature form of SREBP1 protein (Figure 5A).  Overall, the transient elevation in 
triglyceride levels observed is most likely due to the fact that SREBP-1 is transiently 
induced in Ad-5 infected mice. 
 
3.2 ACUTE VS. CHRONIC AD-5 INDUCTION OF SREBP-1 
Since SREBP-1 levels are transiently increased in Ad-5 infected mice, we wanted 
to determine if the response to Ad-5 is acute rather than chronic.  We looked at SREBP-1 
expression levels at later time points post infection.  Livers of Ad-5 infected mice 
sacrificed on day-4, -7, -10, and -14 post infection were screened for SREBP-1 transcripts 
using qPCR.  Compared to uninfected livers, there is an increase in SREBP-1expression in 
day-4 infected livers, but this increase is transient, as we observe a decline in levels of 
SREBP-1 on day-7, -10, and -14 post infection compared to the uninfected livers (Figure 
6A).  This suggests that the effect of Ad-5 on lipid metabolism and SREBP-1 is more 
prominent on day-4 post infection, and not the later time points.  This is most likely due to 
the fact that the mice were only subjected to one infection of Ad-5, and since Ad-5 is a 
replication incompetent virus, it can only undergo one round of infection.  However, we 
also observed a sustained increase in active mature SREBP-1 in nuclear extracts of these 
infected livers as early as day-7 post infection and up until day-14 post infection (Figure 
6B).  These results suggest that the SREBP-1 mRNA levels are transiently expressed with 
Ad-5 infection, but the mature SREBP-1 protein is stably expressed at least until day-14 
post infection.  Also, these results show that Ad-5 induces chronic increase in nuclear pool 
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of SREBP-1, suggesting a chronic effect on systemic lipid metabolism.  This is somewhat 
surprising, as Ad-5 is a replication incompetent virus and is only able to have one round of 
infection, but this one round appears to have lasting effects on systemic lipid metabolism.     
 Our results showed no difference in plasma and liver cholesterol levels in infected 
mice compared to uninfected mice, so we screened these mice for SREBP-2 transcript 
levels using qPCR, as SREBP-2 is a transcription factor that is responsible for activation of 
enzymes involved in synthesis of cholesterol.  SREBP-2 transcript levels were not 
significantly changed in Ad-5 infected mice either on day-4 or day-5 post infection (Figure 
5B).  These results correlate with the lack of changes seen in cholesterol at the plasma and 
hepatic levels.  
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AD-5 INFECTION AUGMENTS PLASMA AND LIVER 
TRIGLYCERIDE 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Quantification of triglycerides and cholesterol in control (uninfected) or Ad-5 
infected mice. (A) Plasma lipids, expressed in mg/dl. (B) Liver lipids, expressed as mg per 
g of liver.  * p < 0.05 compared to control. n= 4 mice in each group.  This data is provided 
by courtesy of Dr. Palmer Wilkins (PostDoc in Department of Biochemistry).   
B. 
A. 
                  * 
                             
* 
                             
* 
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AD-5 INFECTION INDUCES SREBP-1 PROTEIN IN INFECTED 
LIVER TISSUE 
 
 
 
 
 
 
 
 
Figure 4.  Liver homogenates from control and Ad-5 mice sacrificed day-4 post infection 
were subjected to western blot analysis and probed for SREBP-1 (~125 kD precursor 
form).  SREBP-1 signal was normalized to actin.  The antibody used detects both forms of 
SREBP-1 – SREBP-1a and SREBP-1c; but mostly SREBP-1c in the liver.  * p < 0.05 
compared to control.!  This figure is provided by courtesy of Dr. Palmer Wilkins (Post Doc 
in Department of Biochemistry).!
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SREBP-1 and ACC ARE INDUCED IN AD-5 INFECTED LIVERS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Real time qPCR quantifying mRNA expression level of (A) SREBP-1 and 
ACC.  SREBP-1 and ACC are significantly increased on day-4; ACC is significantly 
increased on day-4 and -5.  (B) Quantification of SREBP-2 mRNA.  SREBP-2 is not 
significantly different from control on either day-4 or -5. * p < 0.05 compared to control. 
n=4 mice in each group.  This data is provided by courtesy of Dr. Palmer Wilkins 
(PostDoc in Department of Biochemistry). 
A. 
B. 
* 
 
 * 
 
   * 
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INCREASED SREBP-1 IS SUSTAINED IN AD-5 INFECTED LIVERS 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  (A). Quantification of hepatic SREBP-1 mRNA expression levels.  SREBP-1 is 
transiently expressed on day-4 post infection.  (B).  Nuclear extracts were subjected to 
western blot analysis and probed for nuclear SREBP-1 (~65kD in size).  SREBP-1 protein 
is sustained up until day-14 post infection.  n=1. 
B. 
A. 
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3.3 MECHANISM OF AD-5 INDUCTION 
  
 Our next goal was to characterize the mechanism by which Ad-5 induces SREBP-1, 
leading to an overall increase in triglyceride synthesis.  To do this, we wanted to employ a 
human cultured cell line that could be readily manipulated, both genetically and with small 
molecule inhibitors.  This cell line is the hepatocellular carcinoma cell line (HepG2 cells), 
which comes from the liver.  Our first step was to see if we can replicate the results we 
observed in Ad-5 infected mice to determine whether SREBP-1 is directly induced as a 
result of the Ad-5 infection.  HepG2 cells were infected with Ad-5 at multiplicity of 
infection (MOI) of 15, and then harvested at 72 hours post infection.  Cell homogenates 
were subjected to western blot analysis, and then screened for SREBP-1 protein.  We 
observed that SREBP-1 was significantly increased in Ad-5 infected HepG2 cells (Figure 
7).  This was an indication that we could use HepG2 cells to elucidate the mechanism of 
Ad-5. 
 
 It is known that insulin induces hepatic SREBP-1, but not SREBP-2 expression 
levels through the induction of the PI3K pathway, leading to an overall increase in fatty 
acid synthesis (Taniguchi et al., 2006).  HCV infection has also been shown to mediate its 
effects through the PI3K pathway (Banerjee et al., 2010).  More importantly, it has been 
pointed out that Ad-5 brings about activation of the PI3K pathway upon internalization 
into its target cells (Nemerow et al., 1998).  Based on these observations, we hypothesized 
that Ad-5 mediates its effects through PI3K, and induces SREBP-1 expression.   
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 In order to look at the mechanism by which Ad-5 induces SREBP-1, we wanted to 
employ inhibitors of PI3K.  PX-866 is a wortmannin analog that inhibits the p110 alpha 
unit of PI3K, thus preventing activation of its downstream targets such as Akt and PKC 
!/"/!.  LY924002 is another PI3K inhibitor that acts as a competitive inhibitor by 
competing for the ATP binding site on PI3K (Howes et al., 2007).  Although LY294002 
has been shown to cause high hepatotoxicity, we still wanted to employ both of the 
inhibitors in our study, but LY294002 was used in lower concentrations.    
 
  Our first step was to see if inhibition of PI3K, using either of the two inhibitors 
would suppress Ad-5 induction of SREBP-1.  HepG2 cells were pretreated for 2 hours with 
either the PX-866 or LY294002 inhibitors at concentrations of 15uM and 30uM, and 10uM 
and 20uM, respectively.  Following pretreatment, cells were infected with Ad-5 at MOI of 
15 and harvested at 72 hours post infection.  Again, cell homogenates were subjected to 
western blot analysis, and probed for SREBP-1.  With treatment of PX-866 at 15uM, we 
observed about 42% suppression of Ad-5 induced SREBP-1, while at 30uM of PX-866, 
there was about 52% suppression of Ad-5 induced SREBP-1 levels (Figure 8).  Similar 
results were obtained with the use of LY294002 at 10uM, in which we see 40% 
suppression of SREBP-1, and at 20uM there is about 45% suppression of Ad-5 induced 
SREBP-1 (Figure 8).  Overall, we concluded that PI3K is required for the optimal 
induction of SREBP-1.  These results implicate that Ad-5 mediates its effects through the 
activation of PI3K, thus bringing about an increase in SREBP-1.   
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AD-5 INFECTION INDUCES SREBP-1 IN HEPG2 CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  HepG2 cells were infected with Ad-5 at MOI of 5 or 15 and harvested 4-days 
post infection.  Homogenates were subjected to western blot analysis and probed for 
SREBP-1 (precursor form ~125kD in size).  SREBP-1 is significantly increased in MOI 5 
or MOI 15 infected HepG2 cells compared to uninfected cells.  SREBP-1 protein was 
normalized to actin.  Fold change in SREBP-1 from three different experiments. * p < 0.05 
compared to uninfected.  This figure is provided by courtesy of Dr. Palmer Wilkins (Post 
Doc in Department of Biochemistry). 
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THE PI3K PATHWAY IS REQUIRED FOR THE OPTIMAL 
INDUCTION OF SREBP-1 
 
 
 
 
  
 
 
  
 
 
 
 
 
Figure 8.  HepG2 cells were treated either with PX866, LY294002, or DMSO vehicle at 
indicated concentrations.  Two hours post treatment, cells were infected with Ad-5 at MOI 
of 15 and harvested 72 hours post infection.  Homogenates were subjected to analysis and 
probed for SREBP-1 (precursor form ~125kD in size).  SREBP-1 was normalized to actin.  
Percent inhibition of induced SREBP-1 are as indicated. n=2. This figure is provided by 
courtesy of Dr. Palmer Wilkins (Post Doc in Department of Biochemistry). 
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3.4 INDUCTION OF SREBP-1 THROUGH PKC !/"/!  
 So far we have observed an increase in SREBP-1 in Ad-5 infected HepG2 cells, as 
well as a suppression of induced levels of SREBP-1 with the use of a PI3K inhibitor, either 
PX-866 or LY294002.  Our next goal was to see whether Ad-5 promotes activation of 
downstream effectors of PI3K pathway.  These downstream effectors include Akt and the 
atypical PKC !/"/!.  One way to look at the activation of these effectors is to look for their 
phosphorylated levels.  We infected HepG2 cells with Ad-5 at MOI of 15, and then 
harvested them at 72 hours post infection.  We screened cell homogenates for 
phosphorylated levels of Akt, as well as the atypical PKC !/"/!.  Both Akt and PKC !/"/! 
are activated with Ad-5 infection (Figure 9A and 9B).  PKC!/"/! is phosphorylated as early 
as 20 minutes post infection, but begins to decline at around 24 hours post infection 
(Figure 9A).  Akt is also phosphorylated as early as 20 minutes post infection, but this 
phosphorylation is sustained up until 72 hours post infection (Figure 9B).  These results 
strengthen our hypothesis that Ad-5 brings about activation of PI3K and its downstream 
targets.  This was another indication that Ad-5 mediates its effects through the PI3K 
pathway, thus inducing Akt and PKC!/"/!.  
  
 Up until now, our data points out that Ad-5 selectively induces SREBP-1 and brings 
about an increase in hepatic and lipid triglyceride levels, and this is potentially conducted 
through the induction of PI3K and its effectors Akt and PKC!/"/!.  PKC!/"/! is essential 
for insulin-stimulated lipid synthesis.  The mechanism of how PI3K pathway generates the 
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upregulation of SREBP-1 is yet not well understood, but it has been shown that Akt is 
responsible for mediation of insulin-dependent hepatic glucose metabolism, while PKC 
!/"/! has been linked to the insulin-dependent induction of expression of SREBP-1 
(Taniguchi et al., 2006).   Since we observed activation of both Akt and PKC!/"/!, perhaps 
we could delineate the mechanism of Ad-5 and potentially explain the role Akt and 
PKC!/"/! play in inducing SREBP-1 and its targets.   
  
 With the use of PI3K inhibitors, we were able to demonstrate that PI3K is needed for 
the optimal induction of SREBP-1 upon Ad-5 infection.  Work conducted by Dr. Kahn 
delineates the roles the effectors of the PI3K pathway play in hepatic metabolism 
(Taniguchi et al., 2007).  Since PKC !/"/! is important in regulation of insulin-dependent 
induction of SREBP-1, we wanted to explore this further in our study by using a specific 
inhibitor of PKC !/"/!.  One such specific inhibitor is myristoylated PKC!/"/! peptide 
inhibitor.  It acts as a pseudosubstrate peptide to inhibit PKC!/"/! activity.  We took 
HepG2 cells and pretreated them with 25uM of the inhibitor for 2 hours, followed by Ad-5 
infection at MOI of 15.  Next day, cells were replenished with new media or with the 
inhibitor.  At 72 hours post infection, cells were harvested and subjected to analysis.  
Inhibition of PKC !/"/! suppressed SREBP-1 expression levels by about 60% in Ad-5 
infected HepG2 cells (Figure 10).  These results are comparable to the effects we see with 
the use of a specific PI3K inhibitor, in which we observe about 50% suppression of Ad-5 
induced SREBP-1 levels (Figure 8).  Our results not only strengthen our hypothesis that 
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Ad-5 mediates its effects through PI3K and PKC!/"/!, thus inducing SREBP-1, but it also 
supports work by Dr. Kahn in which they have shown active PKC!/"/! induces SREBP-1 
levels in WT mice (Taniguchi et al., 2006).   
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PKC! /" /#  and AKT ACTIVATION IN AD-5 INFECTED HEPG2 
CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  Ad-5 infected hepatic homogenates were screened for phosphorylated levels of 
(A) PKC and (B) AKT.  (A) Phosphorylated levels of PKC are increased as early as 20 
minutes post infection, but begin to decline at around 12 hours post infection.  (B) 
Phosphorylated levels of Akt are elevated as early as 20 minutes and this increase is 
sustained at 72 hours post infection.  Figure 9A and 9B are representative of three different 
experiments. Figure 9B is provided by Dr. Palmer Wilkins (PostDoc in Biochemistry 
Department, VCU).   
 
 
A. 
B. 
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PKC! /" /#  is REQUIRED FOR THE OPTIMAL INDUCTION OF 
SREBP-1 UPON AD-5 INFECTION 
 
  
 
 
 
 
 
 
 
 
Figure 10.  HepG2 cells were pretreated with myristoylated PKC pan inhibitor, then 
infected with Ad-5 at MOI of 15.  HepG2 cells were harvested at 72 hours post infection, 
subjected to western blot analysis and probed for SREBP-1 (precursor form ~125kD in 
size).  Induced SREBP-1 levels are suppressed by about 100% with the presence of the 
PKC pan inhibitor.  Percent inhibition relative to control.  n=2.   
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3.5 PKC !/"/!  AND AKT KNOCK DOWN IN HEPG2 CELLS 
  
 Although inhibition of PKC!/"/! resulted in suppression of Ad-5 induced SREBP-1 
levels, we wanted to employ a different method since we had several problems with using 
the myristoylated PKC!/"/! inhibitor.  In order to do that, we turned to using siRNA 
targeting PKC!/"/!.  We were able to successfully knock down expression of PKC!/"/! by 
about 60% using siRNA targeting PKC!/"/! (Figure 11A).  We also employed siRNA 
targeting Akt I and II and were able to knock down the expression of Akt by about 40% in 
HepG2 cells (Figure 11B). 
  
 Once we had established the protocol for knocking down PKC!/"/! and Akt in 
HepG2 cells, we were ready to infect HepG2 cells with Ad-5 following the use of siRNA.  
Unfortunately, we ran into a problem with our stock of Ad-5, and are currently working on 
resolving these issues.  So far, that is our last step to delineate the mechanism by which 
Ad-5 brings about activation of SREBP-1, thus altering lipid metabolism.  We believe that 
once we knock down PKC!/"/! using siRNA, and then infect cells with Ad-5, we will be 
able to suppress Ad-5 induced SREBP-1, and demonstrate that this is mediated through 
PKC!/"/! and not Akt, because we believe that with the knock down of Akt, Ad-5 induced 
levels of SREBP-1 would not change.  Therefore, we will be able to show the mechanism 
by which Ad-5 induces SREBP-1.  
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KNOCK DOWN OF PKC! /" /#  and AKT 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  HepG2 cells were subjected to knockdown of (A) PKC!/"/# or (B) Akt.     
 
A. 
B. 
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3.6 AD-5 AND GLUCONEOGENESIS 
  
 A lot of research has been conducted showing that Ad-36 acts as an adipogenic 
agent, increasing adiposity in chickens, rats, and mice (Dhurandhar et al., 2000).  
Dhurandhar et al. group has also shown that Ad-36 upregulates genes such as FAS and 
adiponectin (Dhurandhar et al., 2008).  Our group wanted to study whether the replication 
incompetent Ad-5 would have similar effects on adipogenesis.   
  
 Our first indication that Ad-5 may play a role in adipogenesis was by measuring 
blood glucose levels of Ad-5 infected mice.  Compared to uninfected mice, mice infected 
with Ad-5 and sacrificed 3-days post infection exhibited significantly lower amounts of 
plasma glucose (Figure 12).  This cannot be said for glucose levels measured in day-2 
infected mice, as those levels were only slightly lower than that of uninfected mice (Figure 
12).  This prompted us to look at genes associated with gluconeogenesis, as glucose levels 
are significantly decreased in day-3 Ad-5 infected mice.  One of the critical enzymes in the 
gluconeogenesis pathway is PEPCK (Viollet et al., 2006).  Livers of Ad-5 infected mice 
sacrificed 2- and 3-days post infection were screened for PEPCK expression using qPCR.  
Compared to uninfected livers, there is a slight decrease in PEPCK expression in day-2 
mice, but there is a significant decrease in PEPCK expression in day-3 infected mice 
(Figure 13).   This correlates with a significant decrease in glucose levels in day-3 infected 
mice (Figure 12).  These results prompted us to look at the mechanism by which Ad-5 
potentially decreases gluconeogenesis.  
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3.7 MECHANISM OF AD-5 AND GLUCONEOGENESIS  
  
 Since we have observed decreased blood glucose levels, as well as decreased PEPCK 
expression levels in Ad-5 infected mice, we were prompted to look at the mechanism by 
which Ad-5 mediates these effects.  We wanted to look at the PI3K pathway again, 
because the effects of PI3K have different roles upon activation.  Akt and PKC!/"/! are 
both effectors of the PI3K pathway that are activated upon Ad-5 infection.  Their roles 
diverge upon PI3K activation in which both Akt and PKC !/"/! serve as distinct mediators 
in lipid and glucose homeostasis.  PKC!/"/! is involved in insulin-dependent induction of 
SREBP-1, while Akt is involved in insulin-dependent hepatic glucose metabolism 
(Taniguchi et al., 2006).  Since we have already established that Ad-5 drives the induction 
of SREBP-1 through PKC!/"/!, we wanted to look further at the effects of Ad-5 activation 
of Akt and its role in glucose metabolism.  It has been shown that knock down of Akt 
activity leads to glucose intolerance, and increased expression of gluconeogenic genes such 
as phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) 
(Yang et al., 2004).  More importantly Akt suppresses gluconeogenesis via 
phosphorylation of FoxO1 (Carlsson and Mahlapuu, 2002).  Taken together, these 
evidences prompted our hypothesis that Ad-5 activation of Akt brings about suppression of 
gluconeogenesis. 
  
 Our first step in looking at the mechanism by which Ad-5 mediates reduced blood 
glucose levels was by looking at Akt activation.  We have observed Akt activation with 
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Ad-5 infection in HepG2 cells (Figure 9B), but we wanted to see if the same would hold 
true when we looked at Akt phosphorylation in Ad-5 infected livers.  Activation of Akt in 
Ad-5 infected livers is about 2-fold higher than in uninfected control livers (Figure 14).  
Despite an elevation in total mass of Akt, phosphorylated levels of Akt are significantly 
increased in Ad-5 infected livers, suggesting that Akt activation could be the path forward 
to delineating the mechanism by which reduced blood glucose is observed in Ad-5 infected 
mice.  This would also support Dr. Kahn’s research, which points out that Akt is 
responsible for mediating insulin-induced glucose metabolism (Taniguchi et al., 2006).  
Overall, we were prompted to look at Akt downstream targets that are involved in glucose 
metabolism.  One such target is FoxO1.  It is known that once FoxO1 is phosphorylated, it 
is sequestered from the nucleus in the cytoplasm, and therefore is unavailable for 
activation of gluconeogenic genes (Weickert and Pfeiffer, 2006).  So our next goal was to 
look at FoxO1 expression levels in Ad-5 infected and unifected livers.  Unfortunately, 
much of our attempts were unsuccessful, and we were unable to target FoxO1 in Ad-5 
infected and uninfected livers.  We attempted to probe for FoxO1 in nuclear extracts, 
cytosolic extracts, and whole cell extracts, but our attempts were unsuccessful.  This posed 
a problem, because we wanted to determine if indeed activation of Akt brings about 
sequestration of FoxO1 in Ad-5 infected livers.   
  
 Since we were unable to probe for FoxO1 in Ad-5 infected livers, we wanted to look 
at an alternative novel mechanism of AMPK.  Research has suggested that AMPK can 
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directly phosphorylate FoxO1 and bring about a decrease in gluconeogenic genes such as 
PEPCK and G6Pase (Barthel et al., 2002).  So our next step was to look at phosphorylated 
levels of AMPK in the liver.  This turned out to be more doable as we observed an increase 
in p-AMPK levels in Ad-5 infected mice (data not shown).  Although the increase is 
modest, it implicates that even the slightest changes in p-AMPK can bring about changes 
to overall glucose levels. 
  
 Next, we wanted to explore a mechanism by which AMPK gets activated.  Research 
conducted by Dhurandhar et al., suggests that Ad-36 infected adipose tissue has increased 
transcript levels of adiponectin (Dhurandhar, et al., 2008).  Adiponectin is an adipokine 
produced in adipose tissue that is usually associated with decreased adiposity.  In findings 
of Dhurandhar et al., Ad-36 infection promotes the increase in adiponectin, and is 
associated with an activation of adipogenesis and increased glucose disposal (Rogers et al., 
2008).  Since our data shows decreased levels of glucose on day-3 post infection (Figure 
12), we wanted to look at adiponectin levels in Ad-5 infected livers to determine whether 
there is a link between adiponectin activating AMPK, thus bringing about changes in blood 
glucose.   Thankfully, we were able to send our samples to Dr. Dhurandhar to screen for 
mRNA transcripts of adiponectin.  Based on our preliminary results, there is a trend 
towards increase in adiponectin in Ad-5 infected adipose tissue compared to uninfected 
tissue (Figure 15).  This was an indication that adiponectin gets released from adipose 
tissue, binds to its receptor on the liver, and brings about activation of AMPK, which has 
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further implications in glucose metabolism.   
  
 Overall, we believe that there are two working mechanisms that drive the reduction 
of glucose.  One of these mechanisms is the activation of Akt, which then brings about 
phosphorylation of FoxO1, and a decrease in PEPCK expression, while the other 
mechanism is more indirect in which adiponectin gets released from adipose tissue and 
acts on the liver by activating AMPK, which phosphorylates FoxO1, thus decreasing the 
expression of PEPCK.   These two mechanisms converge at FoxO1, and may potentially 
work together to reduce gluconeogenic gene expression and decrease overall blood glucose 
levels.  Although these results are not yet conclusive, they are suggestive that there are two 
mechanisms that potentially drive the reduction of blood glucose in Ad-5 infected mice.  
Further experiments need to be conducted to solidify these results.  
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AD-5 REDUCES BLOOD GLUCOSE IN INFECTED MICE 
 
Figure 12.  Mice were infected at 1 x 10
11 
particles of replication deficient Ad-5 and 
sacrificed at day-2 and -3 post infection.  There is a significant decrease of blood glucose 
on day-3 post infection compared to control mice.  n=3 or 4 mice in each group.  Error bars 
are mean ± standard deviation. * p < 0.05 compared to control. 
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PEPCK EXPRESSION IS DECREASED IN AD-5 INFECTED LIVERS 
 
 
 
Figure 13.  PEPCK mRNA expression was quantified using qPCR.  There is a significant 
decrease of PEPCK in day-3 infected livers compared to control. n=4 mice in each group.  
Error bars are mean ± standard deviation. * p < 0.05 compared to control. 
 
 
 
 
 
 
 
 
 
* 
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AKT ACTIVATION IN AD-5 INFECTED LIVERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.  Mice infected with Ad-5 were harvested at 72 hours post infection.  Liver 
homogenates were screened for phosphorylated levels of Akt.  There is a significant 
increase in p-Akt in Ad-5 infected livers compared to control.  This figure is provided by 
courtesy of Dr. Palmer Wilkins (PostDoc in Department of Biochemistry, VCU). 
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AD-5 INFECTION AUGMENTS EXPRESSION OF ADIPONECTIN IN 
ADIPOSE TISSUE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.  Adiponectin mRNA expression was quantified using qPCR.  Data was 
normalized to actin.  There is a trend for increased adiponectin in Ad-5 infected adipose 
tissue.  n=2 or 3 mice in each group. 
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CHAPTER 4:  DISCUSSION 
This ongoing study encompasses the effects of replication deficient Ad-5 on 
hepatic lipid synthesis, as well as on adipose tissue lipid metabolism.  Based on previous 
studies and several key observations conducted in our laboratory, we hypothesized that 
replication deficient Ad-5 has an effect on lipid metabolism in hepatic and adipose tissues.   
 
We have observed increased triglyceride levels in Ad-5 infected livers and plasma, 
while cholesterol levels remained unchanged (Figure 3A and 3B).  This observation 
prompted us to look further at SREBP-1 expression levels because SREBP-1 is responsible 
for synthesis of fatty acids and triglycerides (Horton et al., 2002).  Interestingly, SREBP-1 
mRNA levels were significantly increased in Ad-5 infected livers, compared to uninfected 
livers (Figure 5A).  We also screened Ad-5 infected livers for SREBP-2 mRNA 
expression, which remained unchanged; this correlated with the lack of changes seen in 
cholesterol levels in both the liver and plasma (Figure 5B; Figure 3A and 3B).  Ad-5 
infection resembles HCV infection, in which there is an increase in SREBP-1.  Where the 
two viruses differ, is in the fact that HCV infection has been shown to alter expression of 
not only SREBP-1, but SREBP-2 as well (Siddiqui et al., 2009; Koike et al., 2010).  HCV 
is also associated with reduced serum cholesterol levels, but no significant change in 
triglyceride levels.  Overall, these changes lead to lipid accumulation, visceral fat obesity, 
and insulin resistance (Saito et al., 2007).  
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Taken together, our data points to the fact that Ad-5 has implications in aberrant 
lipid metabolism in hepatic tissues.  More importantly, based on Ad-5 infection in cultured 
hepatocytes, we believe that the increase in SREBP-1 is a direct measure of Ad-5 
interaction with the liver, and is most likely not a due to a systemic effect that the virus 
might potentially have on the organism.  This is in contrast to the Ad-5 effect on 
gluconeogenesis, which is potentially mediated indirectly through adipose tissue.   Another 
interesting observation in this study was that even though SREBP-1 mRNA levels are 
transiently expressed in Ad-5 infected livers, mature SREBP-1 protein was still stably 
expressed as far as 14-days post infection.  Despite this stable expression, there were no 
stable increases in plasma triglyceride levels (data not shown).  This is a puzzling finding, 
but a plausible explanation could be based on the fact that other factors are driving 
triglyceride levels back to baseline.  For instance, we have observed an increase in 
phosphorylated levels of AMPK (p-AMPK) due to adiponectin signaling from adipose 
tissue (Figure 14).  p-AMPK could then phosphorylate one of its downstream factors, 
ACC, therefore inhibiting its activity, and thereby fatty acid synthesis;  this inhibition 
favors the %-oxidation pathway (Viollet et al., 2006).  This would drive break down of fatty 
acids, therefore suppress Ad-5 induced triglyceride levels.  Further long-term infections 
need to be conducted to see whether this is a reproducible effect.  It would also be 
interesting to determine whether p-ACC is upregulated in Ad-5 infected livers.   
Based on our findings, we wanted to characterize the mechanism by which Ad-5 
induces these changes and brings about an overall increase in SREBP-1.  It is known that 
53 
 
 
insulin mediates its effects through the PI3K pathway, in which it induces hepatic SREBP-
1 expression, leading to an increase in fatty acids and triglyceride synthesis (Taniguchi et 
al., 2006).  It has also been shown that upon internalization of Ad-5 into the target cells, 
PI3K becomes activated (Nemerow et al., 1998).  We wanted to explore the idea that Ad-5 
mediates its effects through the activation of PI3K, thus leading to an increase in SREBP-
1.  With the use of the novel PI3K inhibitor, such as LY294002 or PX866, we were able to 
demonstrate a decrease in the Ad-5 induced levels of SREBP-1 by about 50% (Figure 8).   
This led us to believe that PI3K is required for the optimal induction of SREBP-1.  
Research has shown that not only Ad-5 activates the PI3K pathway, but other adenoviruses 
such as Ad-2 of group C adenoviruses, as well as Ad-36 of group D adenoviruses (Rogers 
et al., 2008; Li et al, 1998).   Perhaps by activating PI3K, Ad-2 and Ad-36 are also able to 
activate SREBP-1 and have similar effects to Ad-5 on lipid metabolism, but as research 
already pointed out Ad-2 does not induce adipogenesis (Rogers et al., 2008).  Therefore, 
the effects that we have characterized may not only be limited to Ad-5, but could extend to 
other adenoviruses, such as Ad-2 and Ad-36.  
 
Since we had evidence that PI3K in needed for the optimal induction of SREBP-1, 
we wanted to delineate the pathway even further to figure out whether SREBP-1 induction 
is conducted through Akt or PKC!/"/!, both of which are downstream effectors of PI3K.  
Dr. Kahn’s research points out that upon activation of Akt and PKC!/"/!, these two 
mechanisms diverge and the effectors are responsible for different systemic effects.  Akt is 
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thought to mediate insulin-dependent hepatic glucose metabolism, while PKC!/"/! is 
linked to the insulin-dependent induction of expression of SREBP1 (Taniguchi et al., 
2006).  It has been shown that upon activation of PKC!/"/!, SREBP-1 is induced in wild 
type livers.  This knowledge led us to believe that we were on the right path and we 
explored the idea that SREBP-1 is induced through activation of PKC!/"/!, due to Ad-5 
infection and activation of PI3K.   
 
 With the use of a human hepatoma cell model (HepG2 cells), we have been able to 
demonstrated elevated levels of phosphorylated PKC !/"/! in Ad-5 infected HepG2 cells.  
Along with this knowledge, we employed a PKC pan inhibitor.  Ad-5 infected HepG2 cells 
in the presence of PKC zeta inhibitor had decreased levels of SREBP-1, which made us 
believe that we were on the right path and that SREBP-1 is induced through the activation 
of PI3K, and its downstream target PKC !/"/!.  Since we had several issues with using the 
PKC pan inhibitor, we wanted to use a different method to test our hypothesis.  We have 
developed protocols for knocking down both PKC !/"/! and Akt in HepG2 cells, but 
unfortunately we could not test our hypothesis because we are currently having issues with 
our stock of Ad-5, although we are trying to resolve them.  Also, further experiments are 
necessary to evaluate the effects of Akt knock down on Ad-5 infected Hepg2 cells to 
confirm that atypical PKC !/"/! is involved in Ad-5 mediated induction of SREBP-1.  We 
believe that once we are able to knock down PKC !/"/! and infect cells with Ad-5, we will 
be able to prove our postulated mechanism that Ad-5 mediates its effects through PI3K, 
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and more importantly through PKC !/"/!, thus bringing about induction of SREBP-1 and 
triglycerides.  We believe that Ad-5 effect on SREBP-1 induced expression is selective and 
mediated through PKC !/"/!.  With that, if we knock down Akt using siRNA, we also 
believe that it will have no effect on Ad-5 SREBP-1 induced levels.  
 
 Not only does Ad-5 infection play a role in hepatic lipid synthesis, but as we have 
demonstrated, it also plays a vital role in adipose lipid metabolism.  Low blood glucose 
levels in Ad-5 infected mice promoted us to look at the effects of Ad-5 infection on 
adipose tissue (Figure 12).  We have observed that Akt is activated upon Ad-5 infection, 
which is involved in hepatic glucose metabolism (Figure 13).  Studies have also shown that 
adiponectin, an adipocyte-derived hormone, is able to suppress hepatic glucose production 
(Yamauchi et al., 2002).  The Akt pathway and the adiponectin pathway, which activates 
AMPK in the liver, converge at phosphorylation of FoxO1, therefore blocking activation 
of gluconeogenic factors such as PEPCK.  Based on our observed results, we believe that 
Ad-5 blocks gluconeogenesis due to activation of Akt through the PI3K pathway, and 
AMPK through adiponectin signaling from adipose tissue.  Our data correlates with 
published data suggesting that in the presence of Ad-36 infection, there is an increase in 
adiponectin levels, as well as reduced blood glucose levels (Rogers et al., 2008; 
Dhurandhar et al., 2000).   
 
 Together, these findings characterize the effects of Ad-5 infection on lipid 
metabolism.  Replication deficient Ad-5 is an important tool because it is often used as a 
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vector in gene therapy trials.  It is important to further study the effects Ad-5 might have 
on lipid metabolism and adiposity, because they could either interfere with the gene 
therapy trial, or cause secondary effects that would be unwarranted.  Based on our 
findings, we propose that Ad-5 could potentially be one of the factors contributing to fatty 
liver disease, as it has similar effects as HCV, which has been known to cause liver 
cirrhosis and lead to fatty acid accumulation.  Since Ad-5 causes common respiratory 
infections, it is easy to say that many people could be infected with the virus.  Research has 
shown that about 50% of people in the U.S. have antibodies against Ad-5, which is a sign 
that they have been previously infected with the virus (Wang et al., 2008).  Their exposure 
to the virus could lead to increased levels of SREBP-1, and cause an increase in 
triglycerides and fatty acids.  Since our virus is replication incompetent, it merits further 
studies as a replication competent Ad-5 could potentially be more potent because it can 
undergo multiple rounds of infection.   Further studies need to be conducted to test whether 
Ad-5 could potentially be a contributing factor to fatty liver disease, but our research 
points out that Ad-5 is definitely a contributing factor that not only affects lipid 
metabolism in the liver, but also has implications in obesity and Metabolic Syndrome.   
Overall, we believe that Ad-5 infection mediates its effects through the PI3K 
pathway, and activates Akt and PKC !/"/!.  PKC !/"/! further upregulates SREBP-1, which 
drives the increase in triglycerides.  Akt, on the other hand potentially phosphorylates 
FoxO1, which inhibits PEPCK expression and reduces blood glucose levels.  Another 
piece of the puzzle involves the adipose tissue, which upon Ad-5 infection, releases 
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increased levels of adiponectin. Upon adiponectin expression, it binds to its receptor on the 
liver and activates AMPK.  Further, p-AMPK is able to phosphorylate Fox-O1 and again 
reduce blood glucose levels (Figure 16).       
 
Together, this research has shown that replication deficient Ad-5, which is often 
used in clinical gene therapy trials, has effects on hepatic lipid synthesis and adipose tissue 
lipid metabolism, which leads to conclude that this common respiratory pathogen may be 
associated with the Metabolic Syndrome, and like HCV, it could be causative for fatty 
liver disease. 
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MODEL OF AD-5 INFECTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Model of Ad-5 infection and its effects on hepatic and adipose tissues. 
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